High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain.

Järviluoma, Annika; Strandin, Tomas; Lülf, Sebastian; Bouchet, Jérôme; Mäkelä, Anna R; Geyer, Matthias; Benichou, Serge; Saksela, Kalle

Järviluoma, Annika; Strandin, Tomas; Lülf, Sebastian; Bouchet, Jérôme; Mäkelä, Anna R; Geyer, Matthias; Benichou, Serge; Saksela, Kalle.

Affiliation

Järviluoma A; Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland.

PLoS One ; 7(7): e40331, 2012.

Article in En | MEDLINE | ID: mdl-22792285

Subject(s)

Anti-HIV Agents/pharmacology; Recombinant Fusion Proteins/pharmacology; Single-Domain Antibodies/pharmacology; nef Gene Products, Human Immunodeficiency Virus/antagonists & inhibitors; Anti-HIV Agents/chemistry; Escherichia coli; HEK293 Cells; Humans; Kinetics; Protein Binding; Proto-Oncogene Proteins c-hck/metabolism; Recombinant Fusion Proteins/biosynthesis; Recombinant Fusion Proteins/chemistry; Single-Domain Antibodies/biosynthesis; Single-Domain Antibodies/chemistry; nef Gene Products, Human Immunodeficiency Virus/biosynthesis; src Homology Domains

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Anti-HIV Agents / Nef Gene Products, Human Immunodeficiency Virus / Single-Domain Antibodies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Type: Article Affiliation country: Finland

Fulltext

XML

PubMed Links

Search on Google